Cited by 55Alzheimer's disease research and treatmentsNeuroscience and Neuropharmacology ResearchGenetics and Neurodevelopmental Disorders

Roles of eukaryotic elongation factor 2 kinase (eEF2K) in neuronal plasticity, cognition, and Alzheimer disease

Open access
Ma, Tao·2023·Journal of Neurochemistry

Abstract

Understanding the molecular signaling mechanisms underlying cognition and neuronal plasticity would provide insights into the pathogenesis of neuronal disorders characterized by cognitive syndromes such as Alzheimer disease (AD). Phosphorylation of the mRNA translational factor eukaryotic elongation factor 2 (eEF2) by its specific kinase eEF2K is critically involved in protein synthesis regulation. In this review, we discussed recent studies on the roles of eEF2K/eEF2 signaling in the context of regulation/dysregulation of cognitive function and synaptic plasticity. We specifically focus on the discussion of recent evidence indicating suppression of eEF2K signaling as a potential novel therapeutic avenue for AD and related dementias (ADRDs). image

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/jnc.15541

Cites

99 of 99 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • eEF2K inhibition shows no evidence of neuronal injury or inflammatory activation in preclinical models.

    “Preclinical models show restoration of LTP, improved memory, and elevated BDNF and synaptic proteins without evidence of neuronal injury or inflammatory activation [147,156].”

    From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [156]

    In “Promises and Caveats” (page unavailable), the review reports that mice lacking eEF2K appeared normal on basic measures and that inhibitor-treated mice had normal gross hippocampal morphology. Those observations offer limited reassurance, but the paper does not report measures establishing an absence of neuronal injury or inflammatory activation in the preclinical models. (LLM, conf=0.84)

    Experimental — accuracy not yet measured
  • In preclinical models, eEF2K inhibition elevates BDNF and synaptic proteins.

    “Preclinical models show restoration of LTP, improved memory, and elevated BDNF and synaptic proteins without evidence of neuronal injury or inflammatory activation [147,156].”

    From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [156]

    In “Repression of eEF2K as a therapeutic strategy,” the review reports that eEF2K inhibition restored dysregulated proteins involved in synaptic function in AD mice, but it does not describe a general elevation of synaptic proteins. In “Knockdown and Overexpression,” it reports the opposite direction for BDNF: eEF2K inhibition decreased dendritic BDNF protein expression. Page numbers are unavailable in our copy. (LLM, conf=0.86)

    Experimental — accuracy not yet measured
  • eEF2K inhibition could stabilize newly potentiated synapses and extend antidepressant duration by sustaining protein synthesis downstream.

    “By sustaining protein synthesis downstream, eEF2K inhibition could stabilize newly potentiated synapses and extend antidepressant duration [147,156,158].”

    From Synaptic Plasticity—Intrinsic Excitability and Antidepressant Discovery (2026) · cites this paper as [156]

    The ‘Roles of eEF2K in synaptic plasticity and cognition: Knockdown and Overexpression’ section links de novo protein synthesis to maintenance of synaptic plasticity and reports facilitated late LTP in eEF2K-knockout mouse hippocampal slices under one stimulation protocol. The therapeutic-strategy section proposes increased protein synthesis as a mechanism for improvement in Alzheimer’s disease models. Neither section supports extending antidepressant duration; the paper’s discussion concerns plasticity and Alzheimer’s disease, not antidepressant effects. Page numbers were unavailable in our copy. (LLM, conf=0.84)

    Experimental — accuracy not yet measured
  • In preclinical models, eEF2K inhibition improves memory.

    “Preclinical models show restoration of LTP, improved memory, and elevated BDNF and synaptic proteins without evidence of neuronal injury or inflammatory activation [147,156].”
  • In preclinical models, eEF2K inhibition restores LTP.

    “Preclinical models show restoration of LTP, improved memory, and elevated BDNF and synaptic proteins without evidence of neuronal injury or inflammatory activation [147,156].”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Ma, T.
Affiliations
Wake Forest University Health Sciences (US)
Corresponding author
Ma, Tao
ORCID
Ma, Tao
Venue
Journal of Neurochemistry
Publisher
Wiley
Published
2021-11-27
Volume
166
Issue
1
Pages
47-57
ISSN
  • 0022-3042 (ISSN-L)
  • 1471-4159
OpenAlex
W3211922508
Cited by
55
References
99
Citations by year
2026: 10 · 2025: 9 · 2024: 26 · 2023: 4 · 2022: 6
FWCI
1.20
Type
journal article
Language
en
Open access
Locations
  • Journal of Neurochemistry (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Institutes of Health (R01 AG055581, R01 AG056622, R01 AG073823)
  • BrightFocus Foundation (A2017457S)
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Neurodevelopmental Disorders
Keywords
eEF2K, elongation factor 2, eEF2 phosphorylation, mRNA translation regulation, synaptic plasticity, neuroplasticity, cognition, Alzheimer's disease, Alzheimer's disease and related dementias, therapeutic target
MeSH terms
Alzheimer Disease, Cognition, Humans, Neuronal Plasticity, Phosphorylation, Signal Transduction, Peptide Elongation Factor 2, Elongation Factor 2 Kinase

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review